In a meta-analysis conducted on patients with biopsy-proven MASH and fibrosis, GLP-1R agonists were associated with a significantly higher incidence of MASH resolution compared to placebo [245]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.